Compare PAHC & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAHC | ODTX |
|---|---|---|
| Founded | 1946 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2014 | 2025 |
| Metric | PAHC | ODTX |
|---|---|---|
| Price | $38.24 | $17.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $44.00 | $35.33 |
| AVG Volume (30 Days) | 226.1K | ★ 373.8K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | ★ 104.20 | N/A |
| EPS | ★ 2.43 | N/A |
| Revenue | ★ $833,350,000.00 | N/A |
| Revenue This Year | $3.83 | N/A |
| Revenue Next Year | $3.49 | N/A |
| P/E Ratio | $15.61 | ★ N/A |
| Revenue Growth | ★ 4.12 | N/A |
| 52 Week Low | $28.25 | $15.10 |
| 52 Week High | $60.08 | $29.05 |
| Indicator | PAHC | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 58.85 | 37.93 |
| Support Level | $32.97 | $15.10 |
| Resistance Level | $40.65 | $19.60 |
| Average True Range (ATR) | 1.43 | 1.48 |
| MACD | 0.19 | -0.32 |
| Stochastic Oscillator | 71.72 | 16.32 |
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.